I-Mab to seek ap­proval of pe­di­atric growth hor­mone de­fi­cien­cy drug in Chi­na next year af­ter PhI­II win

I-Mab Bio­phar­ma said Thurs­day that its long-act­ing, re­com­bi­nant growth hor­mone can­di­date met the pri­ma­ry end­point in a Phase III tri­al, set­ting the stage for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER